{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:47:37Z","timestamp":1788716857968,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"gw pharmaceuticals, cambridge, uk"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s41669-021-00296-1","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T09:02:43Z","timestamp":1631696563000},"page":"105-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-150X","authenticated-orcid":false,"given":"Siu Hing","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-3528","authenticated-orcid":false,"given":"Jade","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-8914","authenticated-orcid":false,"given":"Hanna","family":"Skrobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"296_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243\u201354.","journal-title":"Pediatr Neurol"},{"key":"296_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d\u2019Aug\u00e8res GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) \u2013 baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12:2.","journal-title":"Orphanet J Rare Dis"},{"key":"296_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/epi4.12286","volume":"4","author":"R Nabbout","year":"2019","unstructured":"Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA study. Epilepsia Open. 2019;4:73\u201384.","journal-title":"Epilepsia Open."},{"key":"296_CR4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/epi.13467","volume":"57","author":"A Jeong","year":"2016","unstructured":"Jeong A, Wong M. Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1443\u20139.","journal-title":"Epilepsia"},{"key":"296_CR5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2018.06.011","volume":"391","author":"J Song","year":"2018","unstructured":"Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, et al. Epilepsy treatment patterns among patients with tuberous sclerosis complex. J Neurol Sci. 2018;391:104\u20138.","journal-title":"J Neurol Sci"},{"key":"296_CR6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","volume":"16","author":"P Curatolo","year":"2012","unstructured":"Curatolo P, J\u00f3\u017awiak S, Nabbout R. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2012;16:582\u20136.","journal-title":"Eur J Paediatr Neurol"},{"key":"296_CR7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","volume":"51","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51:1236\u201341.","journal-title":"Epilepsia"},{"key":"296_CR8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/dmcn.14356","volume":"62","author":"C Tye","year":"2020","unstructured":"Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long-term cognitive outcomes in tuberous sclerosis complex. Dev Med Child Neurol. 2020;62:322\u20139.","journal-title":"Dev Med Child Neurol"},{"key":"296_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajmg.c.31637","volume":"178","author":"PJ de Vries","year":"2018","unstructured":"de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA, Curatolo P. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). Am J Med Genet C Semin Med Genet. 2018;178:309\u201320.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"296_CR10","doi-asserted-by":"crossref","first-page":"a022426","DOI":"10.1101\/cshperspect.a022426","volume":"5","author":"CE Stafstrom","year":"2015","unstructured":"Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5:a022426.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"296_CR11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2009.06.005","volume":"18","author":"K Gallop","year":"2009","unstructured":"Gallop K, Wild D, Nixon A, Verdian L, Cramer JA. Impact of Lennox-Gastaut syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18:554\u20138.","journal-title":"Seizure."},{"key":"296_CR12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2009.10.007","volume":"19","author":"K Gallop","year":"2010","unstructured":"Gallop K, Wild D, Verdian L, Kerr M, Jacoby A, Baker G, et al. Lennox-Gastaut syndrome (LGS): development of conceptual models of health-related quality of life (HRQL) for caregivers and children. Seizure. 2010;19:23\u201330.","journal-title":"Seizure."},{"key":"296_CR13","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1177\/0883073815575364","volume":"30","author":"AM Rentz","year":"2015","unstructured":"Rentz AM, Skalicky AM, Pashos CL, Liu Z, Magestro M, Pelletier CL, et al. Caring for children with tuberous sclerosis complex: what is the physical and mental health impact on caregivers? J Child Neurol. 2015;30:1574\u201381.","journal-title":"J Child Neurol"},{"key":"296_CR14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10198-017-0928-0","volume":"19","author":"BF Wijnen","year":"2018","unstructured":"Wijnen BF, Mosweu I, Majoie MH, Ridsdale L, de Kinderen RJ, Evers SM, et al. A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur J Health Econ. 2018;19:861\u201370.","journal-title":"Eur J Health Econ"},{"key":"296_CR15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11136-016-1483-3","volume":"26","author":"C Mukuria","year":"2017","unstructured":"Mukuria C, Young T, Keetharuth A, Borghs S, Brazier J. Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. Qual Life Res. 2017;26:749\u201359.","journal-title":"Qual Life Res"},{"key":"296_CR16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.pediatrneurol.2014.11.013","volume":"52","author":"AM Rentz","year":"2015","unstructured":"Rentz AM, Skalicky AM, Liu Z, Wheless JW, Dunn DW, Frost MD, et al. Tuberous sclerosis complex: a survey of health care resource use and health burden. Pediatr Neurol. 2015;52:435\u201341.","journal-title":"Pediatr Neurol"},{"key":"296_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13023-019-1258-3","volume":"15","author":"JP Z\u00f6llner","year":"2020","unstructured":"Z\u00f6llner JP, Franz DN, Hertzberg C, Nabbout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15:23.","journal-title":"Orphanet J Rare Dis"},{"key":"296_CR18","unstructured":"The Tuberous Sclerosis Association (TSA) [Internet]. https:\/\/tuberous-sclerosis.org\/author\/nsqj26bxbz\/. Accessed 11 Dec 2020."},{"key":"296_CR19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s11136-019-02117-9","volume":"28","author":"F Hall","year":"2019","unstructured":"Hall F, de Freitas HM, Kerr C, Ito T, Nafees B, Lloyd AJ, et al. Estimating utilities\/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res. 2019;28:1191\u20139.","journal-title":"Qual Life Res"},{"key":"296_CR20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","volume":"56","author":"CE Kosmas","year":"2015","unstructured":"Kosmas CE, Shingler SL, Samanta K, Wiesner C, Moss PAH, Becker U, et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leuk Lymphoma. 2015;56:1320\u20136.","journal-title":"Leuk Lymphoma"},{"key":"296_CR21","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non\u2013small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13:e195-203.","journal-title":"Asia Pac J Clin Oncol"},{"key":"296_CR22","first-page":"1561","volume":"9","author":"BA Fordham","year":"2015","unstructured":"Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, et al. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015;9:1561\u201372.","journal-title":"Patient Prefer Adherence"},{"key":"296_CR23","doi-asserted-by":"crossref","unstructured":"Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Illustrated. Oxford: OUP Oxford; 2001.","DOI":"10.1093\/oso\/9780192631770.001.0001"},{"key":"296_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1\u201330.","journal-title":"J Health Econ"},{"key":"296_CR25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17:445\u201353.","journal-title":"Value Health."},{"issue":"Suppl. 1","key":"296_CR26","first-page":"68","volume":"58","author":"F Amin","year":"2016","unstructured":"Amin F, Mallick A, Lux A, O\u2019Callaghan FJ. Quality of life in children and adults with tuberous sclerosis complex. Dev Med Child Neurol. 2016;58(Suppl. 1):68 (Abstract 125).","journal-title":"Dev Med Child Neurol"},{"key":"296_CR27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ejpn.2019.09.006","volume":"23","author":"S Amin","year":"2019","unstructured":"Amin S, Mallick AA, Lux A, O\u2019Callaghan F. Quality of life in patients with Tuberous Sclerosis Complex (TSC). Eur J Paediatr Neurol. 2019;23:801\u20137.","journal-title":"Eur J Paediatr Neurol"},{"issue":"Suppl. 3","key":"296_CR28","first-page":"S331","volume":"59","author":"B Bennett","year":"2018","unstructured":"Bennett B, Cooper A, Fladrowski C, Evanochko C, Neary M, Vieira J, et al. Assessing quality of life (QOL) in patients with seizures associated with tuberous sclerosis complex (TSC). Epilepsia. 2018;59(Suppl. 3):S331\u20132 (Abstract p724).","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"296_CR29","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jval.2018.09.2088","volume":"21","author":"B Bennett","year":"2018","unstructured":"Bennett B, Cooper A, Fladrowski C, Evanochko C, Neary MP, Vieira J, et al. Patient and caregiver web-based survey: health utilities in tuberous sclerosis complex (TSC) patient population. Value Health. 2018;21(Suppl. 3):S349 (Abstract PND123).","journal-title":"Value Health."},{"key":"296_CR30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/archdischild-2018-316394","volume":"104","author":"CY Fong","year":"2019","unstructured":"Fong CY, Ng K, Kong AN, Ong LC, Rithauddin MA, Thong MK, et al. Quality of life of children with tuberous sclerosis complex. Arch Child. 2019;104:972\u20138.","journal-title":"Arch Child."},{"key":"296_CR31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/13696998.2016.1199432","volume":"19","author":"JC Kingswood","year":"2016","unstructured":"Kingswood JC, Crawford P, Johnson SR, Sampson JR, Shepherd C, Demuth D, et al. The economic burden of tuberous sclerosis complex in the UK: a retrospective cohort study in the Clinical Practice Research Datalink. J Med Econ. 2016;19:1087\u201398.","journal-title":"J Med Econ"},{"key":"296_CR32","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clinph.2015.10.053","volume":"127","author":"A Bernier","year":"2016","unstructured":"Bernier A, Landry JS, Kristof AS, Carmant L, Major P. 2. Characterization of the tuberous sclerosis complex population in the province of Quebec: healthcare services utilization and long term outcome. Clin Neurophysiol. 2016;127:e160.","journal-title":"Clin Neurophysiol"},{"key":"296_CR33","doi-asserted-by":"crossref","first-page":"A137","DOI":"10.1016\/j.jval.2014.03.794","volume":"17","author":"D Demuth","year":"2014","unstructured":"Demuth D, Nasuti P, Lucchese L, Gray L, Pinnegar A, Magestro M. Economic impact of patients with tuberous sclerosis complex (TSC) in the UK: a retrospective database analysis in the clinical practice research datalink (CPRD). Value Health. 2014;17:A137 (Abstract PHS69).","journal-title":"Value Health."},{"key":"296_CR34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1080\/13696998.2016.1202254","volume":"19","author":"JC Kingswood","year":"2016","unstructured":"Kingswood JC, Nasuti P, Patel K, Myland M, Siva V, Gray E. The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: a retrospective cohort study in the clinical practice research datalink (CPRD). J Med Econ. 2016;19:1116\u201326.","journal-title":"J Med Econ"},{"key":"296_CR35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0883073812448437","volume":"28","author":"B Lennert","year":"2013","unstructured":"Lennert B, Farrelly E, Sacco P, Pira G, Frost M. Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. J Child Neurol. 2013;28:461\u20139.","journal-title":"J Child Neurol"},{"key":"296_CR36","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3389\/fneur.2019.01144","volume":"10","author":"R Marques","year":"2019","unstructured":"Marques R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Treatment patterns and use of resources in patients with tuberous sclerosis complex: insights from the TOSCA registry. Front Neurol. 2019;10:1144.","journal-title":"Front Neurol"},{"key":"296_CR37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0883073814523318","volume":"30","author":"AM Skalicky","year":"2015","unstructured":"Skalicky AM, Rentz AM, Liu Z, Wheless JW, Pelletier CL, Dunn DW, et al. The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. J Child Neurol. 2015;30:563\u20139.","journal-title":"J Child Neurol"},{"issue":"7 Suppl.","key":"296_CR38","first-page":"P07.016","volume":"80","author":"D Dunn","year":"2013","unstructured":"Dunn D, Rentz A, Skalicky A, Pelletier C, Liu Z, Prestifilippo J, et al. Characteristics and burden of subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis complex: results of a patient and caregiver survey. Neurology. 2013;80(7 Suppl.):P07.016 (Abstract).","journal-title":"Neurology"},{"issue":"9","key":"296_CR39","first-page":"829","volume":"61","author":"AC Jansen","year":"2017","unstructured":"Jansen AC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Quality of life and burden of disease in tuberous sclerosis complex (TSC): findings from TOSCA research project. J Intellect Disabil Res. 2017;61(9):829 (Abstract).","journal-title":"J Intellect Disabil Res"},{"key":"296_CR40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.yebeh.2019.04.027","volume":"96","author":"C Bar","year":"2019","unstructured":"Bar C, Ghobeira R, Azzi R, Ville D, Riquet A, Touraine R, et al. Experience of follow-up, quality of life, and transition from pediatric to adult healthcare of patients with tuberous sclerosis complex. Epilepsy Behav. 2019;96:23\u20137.","journal-title":"Epilepsy Behav"},{"key":"296_CR41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.yebeh.2008.05.010","volume":"13","author":"CM Kopp","year":"2008","unstructured":"Kopp CM, Muzykewicz DA, Staley BA, Thiele EA, Pulsifer MB. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav. 2008;13:505\u201310.","journal-title":"Epilepsy Behav"},{"key":"296_CR42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2018.03.012","volume":"83","author":"P Both","year":"2018","unstructured":"Both P, Ten Holt L, Mous S, Patist J, Rietman A, Dieleman G, et al. Tuberous sclerosis complex: concerns and needs of patients and parents from the transitional period to adulthood. Epilepsy Behav. 2018;83:13\u201321.","journal-title":"Epilepsy Behav"},{"key":"296_CR43","first-page":"8404378","volume":"2017","author":"S Amin","year":"2017","unstructured":"Amin S, Lux A, Khan A, O\u2019Callaghan F. Sirolimus ointment for facial angiofibromas in individuals with tuberous sclerosis complex. Int Sch Res Not. 2017;2017:8404378.","journal-title":"Int Sch Res Not."},{"key":"296_CR44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/pde.12933","volume":"33","author":"C Crall","year":"2016","unstructured":"Crall C, Valle M, Kapur K, Dies KA, Liang MG, Sahin M, et al. Effect of angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers. Pediatr Dermatol. 2016;33:518\u201325.","journal-title":"Pediatr Dermatol"},{"key":"296_CR45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/epi4.12365","volume":"4","author":"M Vergeer","year":"2019","unstructured":"Vergeer M, Ranitz-Greven WL, Neary MP, Ionescu-Ittu R, Emond B, Sheng Duh M, et al. Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. Epilepsia Open. 2019;4:581\u201392.","journal-title":"Epilepsia Open."},{"key":"296_CR46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jir.12609","volume":"63","author":"A McDonald","year":"2019","unstructured":"McDonald A, Goodwin J, Roberts S, Fish L, Vaughan B, Cooper A, et al. \u201cWe\u2019ve made the best of it. But we do not have a normal life\u201d: families\u2019 experiences of tuberous sclerosis complex and seizure management. J Intellect Disabil Res. 2019;63:947\u201356.","journal-title":"J Intellect Disabil Res"},{"key":"296_CR47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/13696998.2018.1487447","volume":"21","author":"AM Skalicky","year":"2018","unstructured":"Skalicky AM, Rentz AM, Liu Z, Said Q, Nakagawa JA, Frost MD, et al. Economic burden, work, and school productivity in individuals with tuberous sclerosis and their families. J Med Econ. 2018;21:953\u20139.","journal-title":"J Med Econ"},{"key":"296_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.yebeh.2018.11.021","volume":"92","author":"T Tritton","year":"2019","unstructured":"Tritton T, Bennett B, Brohan E, Grant L, Cooper A, Fladrowski C, et al. Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: a web-based survey. Epilepsy Behav. 2019;92:213\u201320.","journal-title":"Epilepsy Behav"},{"key":"296_CR49","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801\u201311.","journal-title":"N Engl J Med"},{"key":"296_CR50","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1111\/j.1528-1167.2010.02669.x","volume":"51","author":"S Liang","year":"2010","unstructured":"Liang S, Li A, Zhao M, Jiang H, Yu S, Meng X, et al. Epilepsy surgery in tuberous sclerosis complex: emphasis on surgical candidate and neuropsychology. Epilepsia. 2010;51:2316\u201321.","journal-title":"Epilepsia"},{"key":"296_CR51","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s00415-017-8507-y","volume":"264","author":"S Liang","year":"2017","unstructured":"Liang S, Zhang J, Yang Z, Zhang S, Cui Z, Cui J, et al. Long-term outcomes of epilepsy surgery in tuberous sclerosis complex. J Neurol. 2017;264:1146\u201354.","journal-title":"J Neurol"},{"key":"296_CR52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/brain\/awz411","volume":"143","author":"S Liu","year":"2020","unstructured":"Liu S, Yu T, Guan Y, Zhang K, Ding P, Chen L, et al. Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China. Brain. 2020;143:570\u201381.","journal-title":"Brain"},{"key":"296_CR53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.yebeh.2010.11.003","volume":"20","author":"J Roth","year":"2011","unstructured":"Roth J, Olasunkanmi A, MacAllister WS, Weil E, Uy CC, Devinsky O, et al. Quality of life following epilepsy surgery for children with tuberous sclerosis complex. Epilepsy Behav. 2011;20:561\u20135.","journal-title":"Epilepsy Behav"},{"key":"296_CR54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2010.03.003","volume":"43","author":"N Zamponi","year":"2010","unstructured":"Zamponi N, Petrelli C, Passamonti C, Moavero R, Curatolo P. Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. Pediatr Neurol. 2010;43:29\u201334.","journal-title":"Pediatr Neurol"},{"key":"296_CR55","doi-asserted-by":"crossref","first-page":"e003707","DOI":"10.1136\/bmjopen-2013-003707","volume":"3","author":"G Graffigna","year":"2013","unstructured":"Graffigna G, Bosio C, Cecchini I. Assisting a child with tuberous sclerosis complex (TSC): a qualitative deep analysis of parents\u2019 experience and caring needs. BMJ Open. 2013;3:e003707.","journal-title":"BMJ Open"},{"issue":"Suppl. 1","key":"296_CR56","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ejpn.2017.04.680","volume":"21","author":"I Toldo","year":"2017","unstructured":"Toldo I, Brasson V, Miscioscia M, Bugin S, Manara R, Nosadini M, et al. Neuropsychiatric disorders and psychopathology of children and adolescents with tuberous sclerosis. Eur J Paediatr Neurol. 2017;21(Suppl. 1):e4 (Abstract OC7).","journal-title":"Eur J Paediatr Neurol"},{"key":"296_CR57","unstructured":"The Office for National Statistics (ONS). 2011 UK census [Internet]. 2011. https:\/\/www.ons.gov.uk\/census. Accessed 25 Oct 2020."},{"key":"296_CR58","unstructured":"CHTE methods review. NICE HRQL Task and Finish Group report. [Internet]. 2020. p. 1\u2013115. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/our-programmes\/nice-guidance\/chte-methods-consultation\/Health-related-quality-of-life-task-and-finish-group-report.docx. Accessed 26 Nov 2020."},{"key":"296_CR59","unstructured":"Rowen D, Brazier J, Wong R, Wailoo A. Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available. NICE DSU report (page 48) [Internet]. 2020. http:\/\/nicedsu.org.uk\/measuring-and-valuing-health-related-quality-of-life-when-sufficient-data-is-not-directly-observed\/. Accessed 2 Jun 2021."},{"key":"296_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00490-z","author":"SA Lipman","year":"2020","unstructured":"Lipman SA. Time for tele-TTO? Lessons learned from digital interviewer-assisted time trade-off data collection. Patient. 2020. https:\/\/doi.org\/10.1007\/s40271-020-00490-z.","journal-title":"Patient"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-021-00296-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-021-00296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T20:49:10Z","timestamp":1699476550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-021-00296-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1007\/s41669-021-00296-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"27 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by GW Pharmaceuticals, Cambridge, UK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SHL, AL and HS are employees of Acaster Lloyd Consulting Ltd. JM is an employee of GW Pharma Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The sponsor is adhering to current US and EU requirements so will not make individual deidentified participant data available; however, the protocol and statistical analysis plan will be made available upon request to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was reviewed and received exempt status determination by the Western Institutional Review Board on 7 August 2020, prior to participant recruitment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors met the ICMJE authorship criteria and had full access to relevant data. Neither honoraria nor payments were made for authorship. All authors were involved in the conception and design of the study. SHL, AL, and HS conducted the study and analysed the data. All authors revised the paper critically for intellectual content before providing final approval of the version to be published. All authors agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}